Fingerprint
Dive into the research topics of 'Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically